In Vitro Pharmacokinetics Study Services
Pharmacokinetics is a critical aspect of drug development, providing insights into a drug's ADME properties within the body. In vitro pharmacokinetics studies play a pivotal role in this process, offering a controlled environment to assess a drug candidate's behavior. Our company, a renowned name in the field of immune disease and inflammation research, provides comprehensive in vitro pharmacokinetics study services.
Overview of In Vitro Pharmacokinetics Study
In vitro pharmacokinetics studies involve the evaluation of a drug candidate's ADME properties in laboratory settings. These studies provide valuable data on drug absorption, distribution, metabolism, and elimination, aiding in the prediction of in vivo performance. By utilizing in vitro models, researchers can obtain crucial information about a drug candidate's physicochemical properties, metabolism, and interactions with transporters.
Fig. 1 Case studies of in vitro and in vivo pharmacokinetics. (Majid H., et al., 2021)
In Vitro Model for In Vitro Pharmacokinetics Study
- Cell-Based Models
Cell-based models, such as Caco-2 and MDCK-MDR1 cell lines, are commonly used to evaluate a drug candidate's permeability across the intestinal epithelium or blood-brain barrier. These models provide insights into a drug's ability to be absorbed and distributed within the body, as well as its potential to cross biological barriers. By measuring the permeability of a drug candidate, researchers can assess its bioavailability and optimize its formulation for enhanced absorption.
- Organ-on-a-Chip Models
Organ-on-a-chip models are innovative systems that replicate the complex architecture and functionality of human organs, such as the liver, kidney, and lung. These microfluidic devices incorporate living cells and mimic the physiological conditions of specific organs, allowing for more accurate predictions of drug behavior. Organ-on-a-chip models offer the advantage of studying drug metabolism, toxicity, and transport in a more physiologically relevant context, thus providing valuable data for drug development.
Our Services
Our company, with its expertise in pharmacokinetics study services, offers a comprehensive suite of services for autoimmune diseases and inflammation. By utilizing advanced in vitro models and cutting-edge technologies, we deliver accurate and reliable data to support informed decision-making in drug development. Our tailored study designs, regulatory compliance, and transparent reporting further contribute to the success of our clients' projects.
In Vitro Physicochemical Studies Services
To help researchers optimize drug delivery systems and enhance bioavailability, we offers comprehensive in vitro physicochemical studies to assess critical parameters such as solubility, dissolution, chemical stability, and lipophilicity.
In Vitro Metabolism Studies Services
Our comapny provides in vitro metabolism studies to evaluate drug metabolism pathways, identify metabolites, and assess enzyme involvement. These studies utilize state-of-the-art techniques, such as high-resolution mass spectrometry, to ensure accurate identification and profiling of metabolites.
In Vitro Permeability and Transporter Studies Services
Drug permeability and interactions with transporters significantly impact a drug's absorption and distribution in the body. We offer a comprehensive suite of in vitro permeability and transporter studies, including assays for P-gp, BCRP, SLC transporters, and preclinical hepatic Oatp uptake transporters.
Our Advantages
High Data Quality
Professional Team
One-stop Platform
Cost and Efficiency
As a trusted partner, our company is committed to advancing drug development through the application of in vitro pharmacokinetics studies. If you are interested in our services, please don't hesitate to contact us.
Reference
- Majid, Haidara, Anke Bartel, and Bjoern B. Burckhardt. "Predictivity of standardized and controlled permeation studies: Ex vivo-In vitro-In vivo correlation for sublingual absorption of propranolol." European Journal of Pharmaceutics and Biopharmaceutics 169 (2021): 12-19.